ADI-270 / Adicet Bio - LARVOL DELTA

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates (Businesswire) - "Patient enrollment is underway in the Phase 1 clinical trial evaluating ADI-270 in adults with relapsed or refractory metastatic/advanced ccRCC. Adicet expects to share preliminary clinical data from the trial in 2H/2025."

P1 data • Trial status • Clear Cell Renal Cell Carcinoma

A phase 1/2 first in human study of ADI-270, an armored allogeneic anti-CD70 chimeric antigen receptor γδ T cell therapy, in relapsed or refractory (R/R) clear cell renal cell carcinoma (ccRCC). (ASCO 2025) - P1/2 | "Clinical Trial Registration Number: NCT06480565 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

P1/2 data • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Solid Tumor • CD70

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting (Businesswire) - "Adicet Bio...today announced the acceptance of an abstract for an oral presentation at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting taking place May 13-17, 2025, in New Orleans, LA."

Preclinical • Solid Tumor

ADI-270, an Armored Allogeneic Anti-CD70 CAR γδ T Cell Therapy, Demonstrates Robust CAR-Directed and -Independent Anti-Tumor Activity Against Hematologic and Solid Tumor Models Compared to Conventional CAR αβ T Cells (ASGCT 2025) - "These favorable preclinical efficacy and safety characteristics support the clinical development of ADI-270 to address multiple CD70 + cancers. Disease Focus of Abstract:Cancer Solid Tumors"

IO biomarker • Preclinical • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor • CD27 • CD70 • TGFB1

A phase 1/2 first in human study of ADI-270, an armored allogeneic anti-CD70 chimeric antigen receptor (CAR)γδT cell therapy, in patients (pts) with relapsed or refractory (R/R) clear cell renal cell carcinoma (ccRCC) (trial in progress) (AACR 2025) - P1/2 | "Additional efficacy analyses include duration of response, progression free survival, and overall survival. Enrollment in study ADI-202427001 is ongoing."

Clinical • IO biomarker • P1/2 data • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Hematological Malignancies • Oncology • Solid Tumor • CD27 • CD70 • TGFB1 • TNFA

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress (Businesswire) - "In December 2024, Adicet announced the dosing of the first patient in the Phase 1 clinical trial evaluating the safety and efficacy of ADI-270 in adults with relapsed or refractory metastatic/advanced ccRCC. Preliminary clinical data from the trial are anticipated in the first half of 2025."

P1 data • Clear Cell Renal Cell Carcinoma

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting (Businesswire) - "Adicet Bio, Inc...announced the acceptance of two abstracts for poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting taking place March 12-14, 2025, in San Diego, C.A."

P1/2 data • Preclinical • Clear Cell Renal Cell Carcinoma

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma (Businesswire) - "Adicet Bio, Inc...today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced ccRCC...'We anticipate reporting preliminary clinical data from the trial in the first half of 2025.'"

Trial status • Clear Cell Renal Cell Carcinoma

ADI-202427001: A Phase 1/2 Trial of ADI-270 in CcRCC (clinicaltrials.gov) - P1/2 | N=60 | Recruiting | Sponsor: Adicet Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma (Businesswire) - "The Phase 1 multicenter, open-label clinical trial is designed to investigate ADI-270 as monotherapy in adults with relapsed or refractory ccRCC. Following lymphodepletion, patients will be eligible to receive a single dose of ADI-270 with a starting dose level of 3E8 CAR+ cells....Preliminary Phase 1 clinical data expected in the first half of 2025."

P1 data • Trial status • Clear Cell Renal Cell Carcinoma

A phase 1/2 first in human study of ADI-270, an armored allogeneic anti-CD70 chimeric antigen receptor γδ T cell therapy, in patients with relapsed or refractory clear cell renal cell carcinoma (SITC 2024) - P1/2 | "Single ADI-270 dose day 23 post implantation (n=5/group) with complete tumor control at both levels. Same mice had A498 tumors implanted to opposite flank day 18 post-ADI-270 with inhibited growth of new tumors demonstrating ability to mount 2nd responseDownload figure Open in new tab Download powerpoint Abstract 640 Figure 5 Study ADI-202427001 schema"

Clinical • IO biomarker • P1/2 data • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Hematological Malignancies • Oncology • Solid Tumor • CD27 • CD70 • TGFB1 • TNFA

Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference (Businesswire) - "Adicet Bio, Inc...today announced acceptance of an oral presentation at the upcoming American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene and Cell Therapies for Cancer conference, taking place October 16 – 17, 2024, in Philadelphia, PA."

Clinical • Oncology • Solid Tumor

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates (Businesswire) - "Contingent upon study initiation progress, the Company intends to initiate the Phase 1 clinical trial of ADI-270 in RCC patients in the fourth quarter of 2024 and present preliminary clinical data from the study in the first half of 2025, subject to site initiation and patient enrollment....Enrollment of mantle cell lymphoma (MCL) patients ongoing in ADI-001 Phase 1 GLEAN study. Adicet is continuing to enroll MCL patients in the Phase 1 trial evaluating ADI-001 in relapsed or refractory non-Hodgkin’s Lymphoma. The Company plans to provide a clinical update in the fourth quarter of 2024."

P1 data • P1/2 data • Trial status • Genito-urinary Cancer • Hematological Malignancies • Kidney Cancer • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Renal Cell Carcinoma • Solid Tumor

A Phase 1/2 Trial of ADI-270 in ccRCC (clinicaltrials.gov) - P1/2 | N=60 | Not yet recruiting | Sponsor: Adicet Therapeutics

New P1/2 trial • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma (Businesswire) - "Adicet Bio, Inc...announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-270 for the potential treatment of patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC) who have been treated with an immune checkpoint inhibitor and a vascular endothelial growth factor inhibitor. 'We are pleased that ADI-270, our first ever gamma delta 1 CAR T cell therapy candidate to enter clinical trials for solid tumors, has been granted Fast Track Designation by the FDA'..."

Fast track • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma (Businesswire) - "Adicet Bio, Inc...announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to evaluate ADI-270, an armored allogeneic 'off-the-shelf' gamma delta chimeric antigen receptor (CAR) T cell therapy candidate targeting CD70+ cancers, for the treatment of relapsed/refractory renal cell carcinoma (RCC). The Company plans to initiate a Phase 1 clinical trial to assess the safety and anti-tumor activity of ADI-270 in RCC patients in the second half of 2024."

IND • New P1 trial • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

ADI-270: AN ARMORED ALLOGENEIC ANTI-CD70 CAR GAMMA-DELTA T CELL THERAPY DESIGNED FOR MULTIPLE SOLID AND HEMATOLOGICAL CANCER INDICATIONS (EHA 2024) - "These results demonstrate the activity of ADI-270 in multiple solid and hematological cancers, which includesinnate anti-tumor immunity, potent next-generation CAR targeting, and resilience to attenuation by TGFβ. Based on the functional characterization demonstrated to date, further clinical evaluation of ADI-270 iswarranted in ccRCC and additional CD70+ solid and hematological malignancies. References1."

IO biomarker • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Hematological Disorders • Hematological Malignancies • Lung Cancer • Lymphoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • T Cell Non-Hodgkin Lymphoma • CD27 • CD70 • TGFB1

Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress (Businesswire) - "Adicet Bio, Inc...today announced the acceptance of a poster presentation at the upcoming European Hematology Association (EHA) Hybrid Congress being held in Madrid, Spain from June 13-16, 2024."

Preclinical • Hematological Malignancies • Oncology • Solid Tumor

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting (Businesswire) - "Adicet Bio...announced that an abstract featuring new preclinical data highlighting ADI-270, an armored allogeneic 'off-the-shelf' gamma delta CAR (chimeric antigen receptor) T cell therapy candidate targeting CD70 positive cancers, has been selected for an oral presentation at the ASGCT 27th Annual Meeting....ADI-270 demonstrated potent in vitro cytotoxicity against multiple CD70 positive tumor cell lines expressing varying levels of CD70. ADI-270 demonstrated robust cytotoxicity against heterogeneous CD70 negative and CD70 positive tumor cell cultures, highlighting the potential of gamma delta CAR T cells to be effective against tumors with mixed antigen expression."

Preclinical • Hematological Malignancies • Renal Cell Carcinoma • Solid Tumor

ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T Cell Therapy Designed for Multiple Solid and Hematological Cancer Indications (ASGCT 2024) - "These results demonstrate the activity of ADI-270 in multiple cancers, which includes innate anti-tumor immunity, potent next-generation CAR targeting, and resilience to attenuation by TGFβ. Based on the functional characterization demonstrated to date, further clinical evaluation of ADI-270 is warranted in ccRCC and additional CD70+ cancers. Plain Language Summary: Soon, you will see the emergence of a new experimental cancer treatment in development called ADI-270."

IO biomarker • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Hematological Disorders • Hematological Malignancies • Kidney Cancer • Lung Cancer • Lymphoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • T Cell Non-Hodgkin Lymphoma • CD27 • CD70 • TGFB1

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress (Businesswire) - "The Phase 1 study of ADI-001 in relapsed or refractory non-Hodgkin’s lymphoma (NHL) is ongoing, with enrollment focused on the MCL patient population, which demonstrated the greatest clinical benefit in the June 2023 clinical update. Adicet expects to provide a clinical update on safety, efficacy and 6-month complete response data in MCL patients in the second half of 2024; Adicet remains on track to file an IND for ADI-270 in renal cell carcinoma in the second quarter of 2024 and expects to provide clinical data from a Phase 1 study in the first half of 2025..."

IND • New P1 trial • P1 data • Mantle Cell Lymphoma • Renal Cell Carcinoma

Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024 (Businesswire) - "Hematologic malignancies: Focus enrollment on MCL patients in ongoing Phase 1 GLEAN study. Adicet will focus on the MCL patient population in the ongoing Phase 1 GLEAN study (at dose level 4), which experienced the greatest clinical benefit in the June 2023 update....The Company remains on track to provide an ADI-001 clinical update in the second half of 2024....Renal cell carcinoma: Plan to file IND for ADI-270 in 2Q 2024. Following positive feedback from a pre-IND meeting with the FDA, the Company remains on track to file an IND application for ADI-270 in the second quarter of 2024."

IND • P1 data • Trial status • Mantle Cell Lymphoma • Renal Cell Carcinoma

Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates (Businesswire) - "Adicet has reprioritized its preclinical pipeline to focus on the development of ADI-270 as its lead preclinical candidate for renal cell carcinoma, with potential in other solid tumor indications. The Company has completed a pre-IND meeting for ADI-270 with the U.S. Food and Drug Administration and received positive feedback to support an IND filing in the first half of 2024....The Company expects to file an IND application for ADI-270 in the first half of 2024. Adicet has paused preclinical development of ADI-925 to prioritize corporate resources on IND-enabling activities for ADI-270."

Discontinued • FDA event • IND • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates (Businesswire) - "...'We expect to file an IND for ADI-270 in the first half of 2024, following our IND for ADI-925 in the second half of 2023'."

IND • Oncology

Adicet Bio Presents Positive Preclinical Data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting (Businesswire) - "Adicet Bio...announced preclinical data highlighting ADI-270, an armored allogeneic 'off-the-shelf' gamma delta CAR (chimeric antigen receptor) T cell therapy candidate targeting CD70+ cancers, at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place from May 16-20, 2023, in Los Angeles, CA....ADI-270 demonstrated preclinical proof-of-concept as an armored allogeneic gamma delta CAR T cell therapy candidate utilizing the CD27 natural receptor in a third generation CAR format for targeting CD70-positive cancers....ADI-270 showed significant inhibition of tumor growth in CD70+ tumor cell lines, which was maintained in the presence of TGF beta inhibitory factor, and exhibited improved resistance to killing by host T cell rejection."

Preclinical • Hematological Malignancies • Oncology